Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.
about
Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteersPharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems.A review of the pharmacokinetics and pharmacodynamics of aztreonam.Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms.Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis.In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms.Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosisBiopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 4. Aztreonam.Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model.
P2860
Q33676387-178A41A6-08AA-49C5-B191-E9F713D12B37Q34297656-772AABD5-826E-4ABC-B36D-EF31BD78F9DCQ35005118-BD734A46-1006-4B41-92E8-AFA3D73E9434Q36969982-C5DC6FE6-4E7A-452C-AA68-E0F9D7DB4015Q37656243-23524286-98E9-4D80-A1C6-6604F52DFBE4Q38024091-B42D8B5E-6084-4B96-9CCA-F6532ACDAE99Q38036618-B2328FFC-CCCD-4D46-8D49-EC81F2CC38E0Q38873850-951526F9-6393-4550-8BB3-14E5B702C29DQ40350783-C8D1684D-03A1-4462-B095-1B7C7EBA3B51Q40573594-BE17A2E4-BBEF-41A4-8620-18F0103DEC90Q40702364-73172AE1-3B0E-463A-883F-C0EAFFBC05A7Q41063056-EFB45B5C-EF7B-44AD-B094-C7CF0CA1166CQ41284108-3F65273D-7285-4225-931A-1A77ED27DB18Q41831306-33B9066C-D0F4-4D82-B48D-707E4ECC1469
P2860
Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pharmacokinetics of aztreonam ...... using monte carlo simulation.
@ast
Pharmacokinetics of aztreonam ...... using monte carlo simulation.
@en
type
label
Pharmacokinetics of aztreonam ...... using monte carlo simulation.
@ast
Pharmacokinetics of aztreonam ...... using monte carlo simulation.
@en
prefLabel
Pharmacokinetics of aztreonam ...... using monte carlo simulation.
@ast
Pharmacokinetics of aztreonam ...... using monte carlo simulation.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of aztreonam ...... using monte carlo simulation.
@en
P2093
Alexander A Vinks
Harry G M Heijerman
Johan W Mouton
Ron A A Mathôt
Ronald N van Rossem
P2860
P304
P356
10.1128/AAC.01522-06
P407
P577
2007-06-18T00:00:00Z